INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384294, 'Elagolix', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of elagolix, which is a substrate of both the metabolic isoenzyme and efflux transporter.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of elagolix should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments or a dose adjustment of elagolix may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elagolix should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384295, 'Eliglustat', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.', 'DDInter', 1767317475, 'Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', 'Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384296, 'Elvitegravir', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384297, 'Encorafenib', 'Cenobamate', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may decrease the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. The extent to which CYP450 3A4 inducers may affect encorafenib exposure has not been studied.', 'DDInter', 1767317475, 'Concomitant use of encorafenib with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.', 'Metabolism', 'Concomitant use of encorafenib with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384298, 'Entacapone', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384299, 'Entrectinib', 'Cenobamate', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of entrectinib, which is a substrate of the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384300, 'Enzalutamide', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of enzalutamide, which is primarily metabolized by CYP450 2C8 to its pharmacologically active metabolite, N-desmethyl enzalutamide, and to a lesser extent by CYP450 3A4.', 'DDInter', 1767317475, 'Concomitant use of enzalutamide with potent CYP450 2C8 and/or 3A4 inducers such as carbamazepine, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort should generally be avoided. Moderate inducers such as bosentan, efavirenz, etravirine, modafinil, nafcillin, and nevirapine should also be avoided if possible. The extent to which other, less potent CYP450 3A4 inducers may interact with enzalutamide is unknown. Caution is advised if they are used with enzalutamide.', 'Metabolism', 'Concomitant use of enzalutamide with potent CYP450 2C8 and/or 3A4 inducers such as carbamazepine, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384301, 'Erdafitinib', 'Cenobamate', 'Major', 'Coadministration with moderate inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is induction of CYP450 2C9- or 3A4-mediated metabolism of erdafitinib, which has been shown to be metabolized by these isoenzymes.', 'DDInter', 1767317475, 'According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered. If a moderate CYP450 2C9 or 3A4 inducer is coadministered after the initial dose increase period, the dose of erdafitinib may be increased up to 9 mg once daily based on serum phosphate levels and tolerability. When a moderate CYP450 2C9 or 3A4 inducer is discontinued, the current dose of erdafitinib may be continued in the absence of erdafitinib toxicity.', 'Metabolism', 'According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384302, 'Ergometrine', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384303, 'Ergotamine', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384304, 'Erlotinib', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Alternative treatment lacking CYP450 3A4-inducing activity is recommended in patients receiving erlotinib. If alternative treatment is unavailable and a potent inducer (e.g., carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, St. John''s wort) is to be used for more than a few days, an increase in the dosage of erlotinib should be considered as tolerated at 2-week intervals. Close clinical and laboratory monitoring for altered efficacy and safety, including renal and liver functions and serum electrolytes, is recommended.', 'Metabolism', 'Alternative treatment lacking CYP450 3A4-inducing activity is recommended in patients receiving erlotinib.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384305, 'Erythromycin', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384306, 'Escitalopram', 'Cenobamate', 'Moderate', 'Coadministration with inhibitors of CYP450 2C19 may increase the plasma concentrations of escitalopram, which is primarily metabolized by the isoenzyme. High plasma levels of escitalopram may increase the risk of serious side effects such as QT prolongation, which may lead to arrhythmias including torsade de pointes and sudden death, as well as serotonin syndrome, which is a rare but potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', 'DDInter', 1767317475, 'Caution is advised if escitalopram must be used in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole. Pharmacologic response to escitalopram should be monitored more closely whenever a CYP450 2C19 inhibitor is added to or withdrawn from therapy, and the escitalopram dosage adjusted as necessary. This may be particularly important in patients receiving escitalopram at the upper end of the dosage range. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heartbeat, shortness of breath, or syncope. Patients should also be closely monitored for symptoms of the serotonin syndrome during treatment.', 'Metabolism', 'Caution is advised if escitalopram must be used in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384307, 'Esketamine', 'Cenobamate', 'Moderate', 'Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.', 'DDInter', 1767317475, 'Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants. Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting. Patients should be instructed not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.', 'Synergism', 'Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384308, 'Eslicarbazepine', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384309, 'Esomeprazole', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.', 'DDInter', 1767317475, 'Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384310, 'Estazolam', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384311, 'Esterified estrogens', 'Cenobamate', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384312, 'Estradiol (topical)', 'Cenobamate', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384313, 'Estrone', 'Cenobamate', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384314, 'Estrone sulfate', 'Cenobamate', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384315, 'Eszopiclone', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of zopiclone, which is a substrate of the isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to zopiclone and eszopiclone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hypnotic dosage adjusted if necessary.', 'Metabolism', 'Pharmacologic response to zopiclone and eszopiclone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hypnotic dosage adjusted if necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384316, 'Ethchlorvynol', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384317, 'Ethosuximide', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384318, 'Ethotoin', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384319, 'Etonogestrel', 'Cenobamate', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384320, 'Etoposide', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384321, 'Etravirine', 'Cenobamate', 'Moderate', 'Coadministration with inhibitors of CYP450 2C19, 2C9, and/or 3A4 may increase the plasma concentrations of etravirine, which is a substrate of these isoenzymes.', 'DDInter', 1767317475, 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with CYP450 2C19, 2C9, and/or 3A4 inhibitors.', 'Metabolism', 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with CYP450 2C19, 2C9, and/or 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384322, 'Everolimus', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the blood concentrations and pharmacologic effects of everolimus.', 'DDInter', 1767317475, 'Some manufacturers recommend avoiding concomitant use of everolimus with moderate CYP450 3A4 and/or P-gp inducers such as bosentan, efavirenz, and nevirapine. If concomitant use is required, a dose adjustment of everolimus should be considered to achieve the recommended therapeutic range for the condition being treated. Everolimus whole blood trough levels should be closely monitored during treatment, particularly 2 weeks after a dose increase and 2 weeks after discontinuation of the inducer.', 'Metabolism', 'Some manufacturers recommend avoiding concomitant use of everolimus with moderate CYP450 3A4 and/or P-gp inducers such as bosentan, efavirenz, and nevirapine.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384323, 'Exemestane', 'Cenobamate', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The manufacturer recommends increasing the dosage of exemestane to 50 mg once daily when used with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. However, it has also been suggested that suppression of estrogen levels is not affected by the interaction, thus dosage adjustment of exemestane is not required. The extent to which other, less potent CYP450 3A4 inducers may interact with exemestane is unknown. Caution is advised if they are used with exemestane.', 'Metabolism', 'The manufacturer recommends increasing the dosage of exemestane to 50 mg once daily when used with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384324, 'Ezogabine', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384325, 'Fedratinib', 'Cenobamate', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of fedratinib, which is a substrate of the isoenzyme.', 'DDInter', 1767317475, 'According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided.', 'Metabolism', 'According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384326, 'Felbamate', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384327, 'Felodipine', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384328, 'Fesoterodine', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of fesoterodine''s active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised when fesoterodine is used with CYP450 3A4 inducers. The possibility of diminished therapeutic effects should be considered.', 'Metabolism', 'Caution is advised when fesoterodine is used with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384329, 'Flavoxate', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384330, 'Flibanserin', 'Cenobamate', 'Moderate', 'Coadministration with inhibitors of CYP450 2C19 may increase the plasma concentrations of flibanserin, which is partially metabolized by the isoenzyme. High plasma levels of flibanserin may increase the risk of severe hypotension, syncope, and central nervous system depression.', 'DDInter', 1767317475, 'Caution is advised when flibanserin is used with CYP450 2C19 inhibitors. Patients should be monitored for signs and symptoms of hypotension, syncope, and central nervous system depression.', 'Metabolism', 'Caution is advised when flibanserin is used with CYP450 2C19 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384331, 'Fludrocortisone', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384332, 'Fluoxetine', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384333, 'Fluphenazine', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384334, 'Flurazepam', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384335, 'Glasdegib', 'Cenobamate', 'Major', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of glasdegib with moderate CYP450 3A4 inducers should generally be avoided. If concomitant use cannot be avoided, the glasdegib dose should be increased as tolerated from 100 mg once a day to 200 mg once a day or from 50 mg once a day to 100 mg once a day. Once the moderate CYP450 3A4 inducer has been discontinued for 7 days, the glasdegib dose should return to the dose taken prior to initiating the moderate CYP450 3A4 inducer.', 'Metabolism', 'Concomitant use of glasdegib with moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384336, 'Granisetron', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384337, 'Guanfacine', 'Cenobamate', 'Major', 'Coadministration with inducers of CYP450 3A4 may significantly decrease the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Close monitoring and dosage adjustment should be considered when guanfacine is administered with potent and moderate CYP450 3A4 inducers. For extended-release guanfacine, some manufacturers recommend increasing the dosage up to double the recommended level when initiating therapy in patients who are already receiving a CYP450 3A4 inducer. Further dosage adjustments may be required based on patient tolerance and response. If a CYP450 3A4 inducer is added to existing guanfacine therapy, the guanfacine dosage may be increased up to double the recommended level over 1 to 2 weeks. The dosage should be decreased to the recommended level over 1 to 2 weeks following discontinuation of the CYP450 3A4 inducer.', 'Metabolism', 'Close monitoring and dosage adjustment should be considered when guanfacine is administered with potent and moderate CYP450 3A4 inducers.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384338, 'Halazepam', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384339, 'Haloperidol', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384340, 'Halothane', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 2B6 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 2B6 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384341, 'Diamorphine', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384342, 'Hydromorphone', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384343, 'Hydroxyzine', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384344, 'Ibrutinib', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished therapeutic effects of ibrutinib should be considered when prescribed in combination with CYP450 3A4 inducers. Patients should be closely monitored, and the dosage of ibrutinib adjusted as necessary in accordance with product labeling.', 'Metabolism', 'The potential for diminished therapeutic effects of ibrutinib should be considered when prescribed in combination with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384345, 'Idelalisib', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of idelalisib, which is a substrate of the isoenzyme.', 'DDInter', 1767317475, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384346, 'Ifosfamide', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384347, 'Iloperidone', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384348, 'Imatinib', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of imatinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384349, 'Imipramine', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384350, 'Indinavir', 'Cenobamate', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384351, 'Irinotecan', 'Cenobamate', 'Moderate', 'Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..', 'DDInter', 1767317475, 'The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.', 'Metabolism', 'The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384352, 'Irinotecan (liposomal)', 'Cenobamate', 'Moderate', 'Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..', 'DDInter', 1767317475, 'The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.', 'Metabolism', 'The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384353, 'Isavuconazonium', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).', 'DDInter', 1767317475, 'Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.', 'Metabolism', 'Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384354, 'Isocarboxazid', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384355, 'Isradipine', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384356, 'Istradefylline', 'Cenobamate', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1. No data are available regarding the effects that other, less potent CYP450 3A4 inducers will have on the pharmacokinetics of istradefylline.', 'DDInter', 1767317475, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers. Clinical monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.', 'Metabolism', 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384357, 'Itraconazole', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384358, 'Ivabradine', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivabradine and its active N-desmethylated metabolite, both of which are primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised during concomitant use of ivabradine with CYP450 3A4 inducers. The potential for decreased efficacy of ivabradine should be considered.', 'Metabolism', 'Caution is advised during concomitant use of ivabradine with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384359, 'Ivacaftor', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384360, 'Cenobamate', 'Ixabepilone', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ixabepilone, which is primarily metabolized by the isoenzyme. Subtherapeutic levels of ixabepilone may result.', 'DDInter', 1767317475, 'The use of ixabepilone in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with ixabepilone is unknown. Whenever possible, therapeutic agents with low enzyme induction potential should be considered in patients treated with ixabepilone.', 'Metabolism', 'The use of ixabepilone in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384361, 'Cenobamate', 'Ixazomib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ixazomib, which is a substrate of the isoenzyme. When ixazomib was administered with the potent CYP450 3A4 inducer rifampin, ixazomib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 54% and 74%, respectively.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of ixazomib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of ixazomib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384362, 'Cenobamate', 'Kava', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384363, 'Cenobamate', 'Ketamine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 2B6 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 2B6 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384364, 'Cenobamate', 'Ketoconazole', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384365, 'Cenobamate', 'Lamotrigine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of lamotrigine. The mechanism is unknown.', 'DDInter', 1767317475, 'The potential for diminished therapeutic response to lamotrigine should be considered during coadministration with cenobamate. Clinical and/or laboratory monitoring are advisable whenever cenobamate is added to or withdrawn from therapy, and the lamotrigine dosage adjusted as necessary.', 'Others', 'The potential for diminished therapeutic response to lamotrigine should be considered during coadministration with cenobamate.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384366, 'Cenobamate', 'Lapatinib', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The use of lapatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided.', 'Metabolism', 'The use of lapatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384367, 'Cenobamate', 'Larotrectinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of larotrectinib, which is primarily metabolized by the isoenzyme as well as the efflux transporter.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of larotrectinib should be considered during coadministration with CYP450 3A4 and P-gp inducers. Some authorities advise that concomitant use of larotrectinib with moderate CYP450 3A4 and/or P-gp inducers should be avoided (UK). Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of larotrectinib should be considered during coadministration with CYP450 3A4 and P-gp inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384368, 'Cenobamate', 'Lasmiditan', 'Moderate', 'Coadministration with alcohol or other central nervous system (CNS) depressants may enhance the sedative effects of lasmiditan and increase the likelihood and/or severity of cognitive and/or neuropsychiatric adverse reactions. Patients treated with lasmiditan are at risk of CNS depression, including dizziness and sedation, as well as driving impairment.', 'DDInter', 1767317475, 'Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation. Patients should be advised against driving and other activities that require complete mental alertness for at least 8 hours after lasmiditan is administered.', 'Synergism', 'Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384369, 'Cenobamate', 'Lefamulin', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter.', 'DDInter', 1767317475, 'Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks. Monitor for reduced efficacy of lefamulin if coadministration is necessary.', 'Metabolism', 'Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384370, 'Cenobamate', 'Lemborexant', 'Moderate', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of lemborexant, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of lemborexant with potent or moderate CYP450 3A4 inducers should be avoided.', 'Metabolism', 'Concomitant use of lemborexant with potent or moderate CYP450 3A4 inducers should be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384371, 'Cenobamate', 'Letrozole', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384372, 'Cenobamate', 'Levetiracetam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384373, 'Cenobamate', 'Levobupivacaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.', 'DDInter', 1767317475, '-', 'Metabolism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384374, 'Cenobamate', 'Levocetirizine', 'Moderate', 'Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.', 'DDInter', 1767317475, 'Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384375, 'Cenobamate', 'Levacetylmethadol', 'Major', 'Coadministration with inducers of CYP450 3A4 may increase the peak activity and/or decrease the duration of action of levomethadyl acetate, which is primarily metabolized by the isoenzyme. Induction of CYP450 3A4 also results in increased formation of the active metabolites, nor-LAAM and dinor-LAAM. High plasma levels of these metabolites may increase the risk of QT interval prolongation and serious ventricular arrhythmias such as torsade de pointes.', 'DDInter', 1767317475, 'Close monitoring is recommended if levomethadyl acetate is used with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. The dose or dosing interval may require adjustment if an interaction is suspected. A 12-lead ECG should be performed before initiating levomethadyl acetate therapy, 12 to 14 days after initiating therapy, and periodically thereafter. Patients should be advised to seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Metabolism', 'Close monitoring is recommended if levomethadyl acetate is used with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384376, 'Cenobamate', 'Levonorgestrel', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384377, 'Cenobamate', 'Levorphanol', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384378, 'Cenobamate', 'Linagliptin', 'Moderate', 'Coadministration with potent inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may significantly decrease the plasma concentrations of linagliptin, which is a substrate for both. The interaction may produce subtherapeutic and likely ineffective plasma concentrations of linagliptin.', 'DDInter', 1767317475, 'Due to the potential for reduced efficacy of linagliptin, coadministration with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. For patients requiring use of such drugs, an alternative to linagliptin is strongly recommended. Other known inducers of CYP450 3A4 include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, modafinil, nafcillin, nevirapine, and various other anticonvulsants, although the extent to which they interact with linagliptin is unknown. If concomitant use with these agents is necessary, glycemic control should be closely monitored.', 'Metabolism', 'Due to the potential for reduced efficacy of linagliptin, coadministration with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384379, 'Cenobamate', 'Lithium carbonate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384380, 'Cenobamate', 'Lofexidine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384381, 'Cenobamate', 'Lonafarnib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of lonafarnib. In vitro, lonafarnib has been shown to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 1A2, 2A6, 2C8, 2C9, 2C19, and 2E1.', 'DDInter', 1767317475, 'Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384382, 'Cenobamate', 'Lorazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384383, 'Cenobamate', 'Lorlatinib', 'Major', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lorlatinib, which has been found to be metabolized primarily by CYP450 3A4 and UGT1A4 in vitro. In addition to the potential for diminished efficacy of lorlatinib, the risk of serious hepatotoxicity may be increased due to activation of the pregnane X receptor (PXR) by both lorlatinib and CYP450 3A4 inducers. The effect of concomitant use of moderate CYP450 3A4 inducers on lorlatinib pharmacokinetics or the risk of hepatotoxicity is unknown.', 'DDInter', 1767317475, 'Concomitant use of lorlatinib with moderate CYP450 3A4 inducers should generally be avoided. If coadministration is required, monitoring of AST, ALT and bilirubin is recommended 48 hours after initiating lorlatinib and at least 3 times during the first week of treatment. Depending upon the relative importance of each drug, lorlatinib or the CYP450 3A4 inducer should be discontinued for persistent Grade 2 or higher hepatotoxicity.', 'Metabolism', 'Concomitant use of lorlatinib with moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384384, 'Cenobamate', 'Loxapine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384385, 'Cenobamate', 'Lumateperone', 'Major', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lumateperone, which is metabolized by the isoenzyme in vitro.', 'DDInter', 1767317475, 'Coadministration of CYP450 3A4 inducers with lumateperone should be avoided.', 'Metabolism', 'Coadministration of CYP450 3A4 inducers with lumateperone should be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384386, 'Cenobamate', 'Lurasidone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lurasidone, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of lurasidone should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of lurasidone should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384387, 'Cenobamate', 'Lurbinectedin', 'Major', 'Coadministration with a strong or moderate CYP450 3A4 inducer is predicted to decrease lurbinectedin systemic exposure, which may reduce its efficacy.', 'DDInter', 1767317475, 'Concomitant use of lurbinectedin and strong or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of lurbinectedin and strong or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384388, 'Cenobamate', 'Macimorelin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of macimorelin, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The prescribing information for macimorelin recommends discontinuing potent CYP450 3A4 inducers (e.g., carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, St. John''s wort) as well as some moderate ones (e.g., bosentan, efavirenz, etravirine, modafinil) prior to macimorelin administration. A sufficient washout period following discontinuation of the inducers is also advised before using macimorelin. No recommendations are available for other, less potent CYP450 3A4 inducers; however, it may be appropriate to follow the same precaution.', 'Metabolism', 'The prescribing information for macimorelin recommends discontinuing potent CYP450 3A4 inducers (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384389, 'Cenobamate', 'Macitentan', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of macitentan, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised when macitentan is used with CYP450 3A4 inducers. The possibility of diminished therapeutic effects should be considered.', 'Metabolism', 'Caution is advised when macitentan is used with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384390, 'Cenobamate', 'Maprotiline', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384391, 'Cenobamate', 'Maraviroc', 'Moderate', 'Coadministration with inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may decrease the plasma concentrations of maraviroc, which is a substrate of both.', 'DDInter', 1767317475, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if maraviroc is used with CYP450 3A4 and/or P-glycoprotein inducers. A dosage adjustment for maraviroc may be necessary if an interaction is suspected.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if maraviroc is used with CYP450 3A4 and/or P-glycoprotein inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384392, 'Cenobamate', 'Meclizine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384393, 'Cenobamate', 'Medroxyprogesterone acetate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of medroxyprogesterone, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to medroxyprogesterone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary. When administered as the depot formulation for contraception, no dosage adjustment for medroxyprogesterone is currently recommended during coadministration with CYP450 3A4 inducers.', 'Metabolism', 'Pharmacologic response to medroxyprogesterone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384394, 'Cenobamate', 'Mefloquine', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of mefloquine, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The possibility of diminished therapeutic effects should be considered when mefloquine is used in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from mefloquine therapy, and the dosage adjusted if necessary. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with mefloquine is unknown.', 'Metabolism', 'The possibility of diminished therapeutic effects should be considered when mefloquine is used in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384395, 'Cenobamate', 'Meperidine', 'Moderate', 'The central nervous system and respiratory depressant effects of meperidine may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered, particularly in elderly or debilitated patients.', 'DDInter', 1767317475, 'Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol. A lower dosage of meperidine should be considered initially, then titrated carefully according to pain level and clinical response. Meperidine dosage reductions of 25% to 50% have been recommended for patients receiving phenothiazines and other tranquilizers.', 'Synergism', 'Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384396, 'Cenobamate', 'Mephenytoin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384397, 'Cenobamate', 'Methylphenobarbital', 'Moderate', 'Coadministration with cenobamate may increase the plasma concentrations and pharmacologic effects of phenobarbital. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19, an isoenzyme involved in the hepatic metabolism of phenobarbital.', 'DDInter', 1767317475, 'Caution is recommended during concomitant use of cenobamate and phenobarbital. Clinical and/or laboratory monitoring are advisable whenever cenobamate is added to or withdrawn from therapy, and the phenobarbital dosage adjusted as necessary.', 'Metabolism', 'Caution is recommended during concomitant use of cenobamate and phenobarbital.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384398, 'Cenobamate', 'Meprobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384399, 'Cenobamate', 'Mesoridazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384400, 'Cenobamate', 'Metaxalone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384401, 'Cenobamate', 'Methadone', 'Major', 'Coadministration with inducers of various CYP450 isoenzymes may decrease the plasma concentrations of methadone, which is metabolized by CYP450 3A4, 2B6, 2C19, 2C9, and 2D6. Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on methadone following the addition of an inducer. Conversely, discontinuation of the inducer may increase methadone plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.', 'DDInter', 1767317475, 'Caution is advised if methadone is prescribed with CYP450 2B6, 2C19, 2C9 and/or 3A4 inducers. Pharmacologic response to methadone should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', 'Caution is advised if methadone is prescribed with CYP450 2B6, 2C19, 2C9 and/or 3A4 inducers.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384402, 'Cenobamate', 'Methdilazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384403, 'Cenobamate', 'Methocarbamol', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384404, 'Cenobamate', 'Methotrimeprazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384405, 'Cenobamate', 'Methsuximide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384406, 'Cenobamate', 'Methyldopa', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384407, 'Cenobamate', 'Methylergometrine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384408, 'Cenobamate', 'Methysergide', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384409, 'Cenobamate', 'Metoclopramide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384410, 'Cenobamate', 'Metyrosine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384411, 'Cenobamate', 'Midazolam', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384412, 'Cenobamate', 'Midostaurin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of midostaurin and its active metabolites, which are all substrates of the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of midostaurin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of midostaurin should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384413, 'Cenobamate', 'Mifepristone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of mifepristone, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'When mifepristone is prescribed daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, concomitant use with potent CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and rifamycins should generally be avoided. Other, less potent inducers such as aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants may also interact. Caution is advised if they are used with mifepristone.', 'Metabolism', 'When mifepristone is prescribed daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, concomitant use with potent CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and rifamycins should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384414, 'Cenobamate', 'Mirabegron', 'Minor', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein may decrease the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme and efflux transporter. No dosage adjustment is recommended when mirabegron is administered in combination with rifampin and probably other CYP450 3A4/P-gp inducers.', 'DDInter', 1767317475, '-', 'Metabolism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384415, 'Cenobamate', 'Mirtazapine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of mirtazapine, which is partially metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The possibility of diminished therapeutic response to mirtazapine should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifampin, and St. John''s wort. Pharmacologic response to mirtazapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', 'The possibility of diminished therapeutic response to mirtazapine should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifampin, and St.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384416, 'Cenobamate', 'Modafinil', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to modafinil or armodafinil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Dose adjustments may be required if an interaction is suspected.', 'Metabolism', 'Pharmacologic response to modafinil or armodafinil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384417, 'Cenobamate', 'Molindone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384418, 'Cenobamate', 'Montelukast', 'Moderate', 'Coadministration with inducers of hepatic CYP450 isoenzymes may decrease the plasma concentrations of montelukast, which is metabolized by CYP450 2C8, 2C9, and 3A4 .', 'DDInter', 1767317475, 'No dosage adjustment for montelukast is recommended when used concomitantly with CYP450 inducers. However, clinical monitoring for potentially reduced therapeutic effects may be appropriate, especially for potent inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort.', 'Metabolism', 'No dosage adjustment for montelukast is recommended when used concomitantly with CYP450 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384419, 'Cenobamate', 'Morphine (liposomal)', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384420, 'Cenobamate', 'Nabilone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384421, 'Cenobamate', 'Nalbuphine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384422, 'Cenobamate', 'Naldemedine', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of naldemedine, which is primarily metabolized by CYP450 3A4 to nor-naldemedine and to a minor extent by UGT1A3 to naldemedine 3-G. Both metabolites have demonstrated antagonistic activity for opioid receptors, but with less potency than the parent drug.', 'DDInter', 1767317475, 'Caution and monitoring for potential loss of efficacy is recommended with the concomitant use of naldemedine with moderate CYP450 3A4 inducers.', 'Metabolism', 'Caution and monitoring for potential loss of efficacy is recommended with the concomitant use of naldemedine with moderate CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384423, 'Cenobamate', 'Naloxegol', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of naloxegol, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished therapeutic effects of naloxegol should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of naloxegol should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.', 'Metabolism', 'The potential for diminished therapeutic effects of naloxegol should be considered when prescribed with inducers of CYP450 3A4.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384424, 'Cenobamate', 'Nefazodone', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384425, 'Cenobamate', 'Nelfinavir', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384426, 'Cenobamate', 'Neratinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of neratinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Given the potential for reduced efficacy of neratinib, concomitant use with potent or moderate inducers of CYP450 3A4 should generally be avoided. According to some authorities, if the CYP450 3A4 inducer cannot be avoided, the dose of neratinib should be increased to 320 mg once daily. The daily dose of neratinib should not exceed 320 mg. The previous dose of neratinib may be resumed following discontinuation of the CYP450 3A4 inducer.', 'Metabolism', 'Given the potential for reduced efficacy of neratinib, concomitant use with potent or moderate inducers of CYP450 3A4 should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384427, 'Cenobamate', 'Nevirapine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384428, 'Cenobamate', 'Nicardipine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384429, 'Cenobamate', 'Nicotine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 2B6 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 2B6 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384430, 'Cenobamate', 'Nilotinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of nilotinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Patients receiving nilotinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to nilotinib. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', 'Patients receiving nilotinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to nilotinib.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384431, 'Cenobamate', 'Nimodipine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384432, 'Cenobamate', 'Nintedanib', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384433, 'Cenobamate', 'Nisoldipine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384434, 'Cenobamate', 'Nitisinone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.', 'DDInter', 1767317475, 'Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384435, 'Cenobamate', 'Norgestrel', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384436, 'Cenobamate', 'Nortriptyline', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384437, 'Cenobamate', 'Olanzapine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384438, 'Cenobamate', 'Olaparib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of olaparib with potent and moderate CYP450 3A4 inducers should generally be avoided. If coadministration with a moderate CYP450 3A4 inducer such as bosentan, dexamethasone, efavirenz, etravirine, modafinil or nafcillin is required, the potential for decreased efficacy of olaparib should be considered.', 'Metabolism', 'Concomitant use of olaparib with potent and moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384439, 'Cenobamate', 'Oliceridine', 'Major', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer. Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.', 'DDInter', 1767317475, 'Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.', 'Metabolism', 'Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384440, 'Cenobamate', 'Olopatadine (nasal)', 'Moderate', 'Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.', 'DDInter', 1767317475, 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384441, 'Cenobamate', 'Ondansetron', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384442, 'Cenobamate', 'Opicapone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384443, 'Cenobamate', 'Opium', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384444, 'Cenobamate', 'Orphenadrine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384445, 'Cenobamate', 'Osilodrostat', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or 2B6 may decrease the plasma concentrations of osilodrostat, which is partially metabolized by these isoenzymes. According to the product labeling, multiple CYP450 isoenzymes (CYP450 3A4, 2B6, and 2D6) and UDP-glucuronosyltransferases contribute to osilodrostat metabolism, and no single pathway contributes greater than 25% to the total clearance. Some of the known CYP450 3A4 and 2B6 inducers also induce UDP-glucuronosyltransferases.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of osilodrostat should be considered during concomitant use of a CYP450 3A4 and/or 2B6 inducer. An increase in the dosage of osilodrostat may be required. Dosage adjustments should be based on clinical response and tolerance. Patients should have regular monitoring of 24-hour urine free cortisol and serum or plasma cortisol during treatment, as well as regular evaluations of their signs and symptoms. A reduction in dosage of osilodrostat may be required if the CYP450 3A4 and/or 2B6 inducer is discontinued during treatment with osilodrostat.', 'Metabolism', 'The potential for diminished pharmacologic effects of osilodrostat should be considered during concomitant use of a CYP450 3A4 and/or 2B6 inducer.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384446, 'Cenobamate', 'Osimertinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of osimertinib, which has been shown in vitro to be primarily metabolized by the isoenzyme. Reduced therapeutic efficacy of osimertinib may occur. However, no pharmacokinetic data are available from drug interaction studies.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of osimertinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of osimertinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384447, 'Cenobamate', 'Oxazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384448, 'Cenobamate', 'Oxcarbazepine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384449, 'Cenobamate', 'Oxybutynin', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384450, 'Cenobamate', 'Oxycodone', 'Major', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer. Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.', 'DDInter', 1767317475, 'Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.', 'Metabolism', 'Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384451, 'Cenobamate', 'Oxymorphone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384452, 'Cenobamate', 'Paclitaxel (protein-bound)', 'Moderate', 'Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is metabolized by these isoenzymes.', 'DDInter', 1767317475, 'Clinicians should recognize the potential for interaction with drugs that induce CYP450 2C8 and/or 3A4 and monitor for evidence of reduced therapeutic response to paclitaxel during coadministration.', 'Metabolism', 'Clinicians should recognize the potential for interaction with drugs that induce CYP450 2C8 and/or 3A4 and monitor for evidence of reduced therapeutic response to paclitaxel during coadministration.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384453, 'Cenobamate', 'Palbociclib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.', 'Metabolism', 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384454, 'Cenobamate', 'Paliperidone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384455, 'Cenobamate', 'Panobinostat', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of panobinostat, which is partially metabolized by the isoenzyme. The interaction has not been evaluated clinically, but simulations using physiologically-based pharmacokinetic (PBPK) models suggest an approximately 70% decrease in panobinostat systemic exposure in the presence of potent CYP450 3A4 inducers.', 'DDInter', 1767317475, 'Caution is advised during concomitant use of panobinostat with CYP450 3A4 inducers. The potential for decreased efficacy of panobinostat should be considered.', 'Metabolism', 'Caution is advised during concomitant use of panobinostat with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384456, 'Cenobamate', 'Pantoprazole', 'Moderate', 'Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.', 'DDInter', 1767317475, 'Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384457, 'Cenobamate', 'Paraldehyde', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384458, 'Cenobamate', 'Paramethadione', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384459, 'Cenobamate', 'Paroxetine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384460, 'Cenobamate', 'Pazopanib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of pazopanib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The use of pazopanib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Alternative treatment lacking CYP450 3A4-inducing activity should be considered in patients receiving pazopanib; otherwise, pazopanib should not be used. Other known CYP450 3A4 inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they may interact with pazopanib is unknown.', 'Metabolism', 'The use of pazopanib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384461, 'Cenobamate', 'Pemigatinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro.', 'DDInter', 1767317475, 'Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inducers should be avoided.', 'Metabolism', 'Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inducers should be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384462, 'Cenobamate', 'Pentazocine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384463, 'Cenobamate', 'Pentobarbital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384464, 'Cenobamate', 'Perampanel', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384465, 'Cenobamate', 'Pergolide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384466, 'Cenobamate', 'Perphenazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384467, 'Cenobamate', 'Pexidartinib', 'Moderate', 'Coadministration of pexidartinib with moderate CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of pexidartinib. The proposed mechanism is induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of pexidartinib.', 'DDInter', 1767317475, 'Caution is advised if pexidartinib is used with moderate CYP450 3A4 inducers. It is unknown if pexidartinib will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inducer. Clinical and laboratory monitoring of pexidartinib should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.', 'Metabolism', 'Caution is advised if pexidartinib is used with moderate CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384468, 'Cenobamate', 'Phenacemide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384469, 'Cenobamate', 'Phenelzine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384470, 'Cenobamate', 'Phenindamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384471, 'Cenobamate', 'Phenobarbital', 'Moderate', 'Coadministration with cenobamate may increase the plasma concentrations and pharmacologic effects of phenobarbital. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19, an isoenzyme involved in the hepatic metabolism of phenobarbital.', 'DDInter', 1767317475, 'Caution is recommended during concomitant use of cenobamate and phenobarbital. Clinical and/or laboratory monitoring are advisable whenever cenobamate is added to or withdrawn from therapy, and the phenobarbital dosage adjusted as necessary.', 'Metabolism', 'Caution is recommended during concomitant use of cenobamate and phenobarbital.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384472, 'Cenobamate', 'Phensuximide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384473, 'Cenobamate', 'Phenytoin', 'Major', 'Coadministration of cenobamate and phenytoin may lead to increased plasma concentrations of phenytoin and reduced plasma concentrations of cenobamate. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19, one of the isoenzymes involved in the hepatic metabolism of phenytoin, and phenytoin-mediated induction of some of the metabolic routes of elimination of cenobamate, including CYP450 3A4 and glucuronidation.', 'DDInter', 1767317475, 'The manufacturer of cenobamate recommends that the daily dose of phenytoin be gradually reduced by up to 50% when the dosage of cenobamate is being titrated. Clinical and/or laboratory monitoring are advisable whenever cenobamate is added to or withdrawn from therapy, and the phenytoin dosage adjusted accordingly. Patients should be advised to contact their physician if they experience signs and symptoms of phenytoin toxicity such as nausea, vomiting, tremors, ataxia, lethargy, slurred speech, visual disturbances, or changes in mental status.', 'Metabolism', 'The manufacturer of cenobamate recommends that the daily dose of phenytoin be gradually reduced by up to 50% when the dosage of cenobamate is being titrated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384474, 'Cenobamate', 'Pimavanserin', 'Moderate', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Coadministration of potent or moderate CYP450 3A4 inducers with pimavanserin should be avoided.', 'Metabolism', 'Coadministration of potent or moderate CYP450 3A4 inducers with pimavanserin should be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384475, 'Cenobamate', 'Pimozide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384476, 'Cenobamate', 'Pirfenidone', 'Moderate', 'Coadministration with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 may increase the plasma concentrations of pirfenidone, especially when used in addition to a moderate or potent CYP450 1A2 inhibitor. Pirfenidone is primarily (70% to 80%) metabolized by CYP450 1A2, with minor contribution from CYP450 2C9, 2C19, 2D6, and 2E1.', 'DDInter', 1767317475, 'Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.g., certain fluoroquinolones, oral contraceptives, deferasirox, methoxsalen, mexiletine, thiabendazole, ticlopidine, zileuton) should be avoided. No particular precaution is necessary if pirfenidone and CYP450 2C9, 2C19, 2D6, and/or 2E1 inhibitors are coadministered without a moderate or potent CYP450 1A2 inhibitor.', 'Metabolism', 'Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384477, 'Cenobamate', 'Pitolisant', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384478, 'Cenobamate', 'Polatuzumab vedotin', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384479, 'Cenobamate', 'Pomalidomide', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384480, 'Cenobamate', 'Ponatinib', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of ponatinib, which is a substrate of the isoenzyme.', 'DDInter', 1767317475, 'Coadministration of ponatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided unless the benefit outweighs the potential risk of ponatinib underexposure. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with ponatinib is unknown.', 'Metabolism', 'Coadministration of ponatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384481, 'Cenobamate', 'Pralsetinib', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A may decrease the plasma concentrations of pralsetinib which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of pralsetinib should be considered during coadministration with moderate CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of pralsetinib should be considered during coadministration with moderate CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384482, 'Cenobamate', 'Pramipexole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384483, 'Cenobamate', 'Praziquantel', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of praziquantel, which is a substrate of the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved. Alternative agents for schistosomiasis should be considered whenever possible in patients receiving treatment with a CYP450 3A4 inducer. Otherwise, clinical response to praziquantel should be closely monitored.', 'Metabolism', 'Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384484, 'Cenobamate', 'Prednisolone', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384485, 'Cenobamate', 'Prednisone', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384486, 'Cenobamate', 'Pregabalin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384487, 'Cenobamate', 'Pretomanid', 'Major', 'Coadministration of pretomanid with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and antimicrobial effects of pretomanid, which has been shown to be a substrate of the isoenzyme.', 'DDInter', 1767317475, 'The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided. Dosage adjustments as well as clinical and laboratory monitoring of pretomanid should be considered whenever a strong or moderate CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384488, 'Cenobamate', 'Primidone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384489, 'Cenobamate', 'Prochlorperazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384490, 'Cenobamate', 'Procyclidine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384491, 'Cenobamate', 'Progesterone', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384492, 'Cenobamate', 'Progesterone (topical)', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384493, 'Cenobamate', 'Promazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384494, 'Cenobamate', 'Promethazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384495, 'Cenobamate', 'Propiomazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384496, 'Dextropropoxyphene', 'Cenobamate', 'Major', 'Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Pharmacokinetically, propoxyphene is an inhibitor of CYP450 2D6 and may increase the plasma concentrations of many psychotropic agents that are metabolized by the isoenzyme such as phenothiazines, haloperidol, risperidone, phenobarbital, and some tricyclic antidepressants and serotonin reuptake inhibitors.', 'DDInter', 1767317475, 'Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.', 'Metabolism, Synergism', 'Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384497, 'Cenobamate', 'Propranolol', 'Moderate', 'Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.', 'DDInter', 1767317475, 'Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384498, 'Cenobamate', 'Protriptyline', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384499, 'Cenobamate', 'Mepyramine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384500, 'Cenobamate', 'Quazepam', 'Moderate', 'Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.', 'DDInter', 1767317475, 'Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384501, 'Cenobamate', 'Quetiapine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quetiapine, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary. Patients should be advised to notify their physician if their symptoms worsen or their condition changes.', 'Metabolism', 'Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384502, 'Cenobamate', 'Quinestrol', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', 'DDInter', 1767317475, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384503, 'Cenobamate', 'Quinidine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384504, 'Cenobamate', 'Quinine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quinine, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if quinine is used in combination with CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and St. John''s wort. The possibility of diminished therapeutic efficacy should be considered.', 'Metabolism', 'Caution is advised if quinine is used in combination with CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and St.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384505, 'Cenobamate', 'Ramelteon', 'Moderate', 'Coadministration with inducers of CYP450 isoenzymes may decrease the plasma concentrations and pharmacologic effects of ramelteon, which is metabolized by CYP450 1A2 and, to a lesser extent, by CYP450 3A4 and the 2C subfamily of isoenzymes.', 'DDInter', 1767317475, 'The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St. John''s wort. Other known inducers include aminoglutethimide, bexarotene, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, mitotane, modafinil, nafcillin, nevirapine, rifabutin, rifapentine, barbiturates and various other anticonvulsants, although the extent to which they interact with ramelteon is unknown.', 'Metabolism', 'The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384506, 'Cenobamate', 'Ranolazine', 'Major', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The manufacturer considers the use of ranolazine to be contraindicated in patients taking potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. The extent to which other, less potent CYP450 3A4 inducers may interact with ranolazine is unknown. Caution is advised if they are used with ranolazine.', 'Metabolism', 'The manufacturer considers the use of ranolazine to be contraindicated in patients taking potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384507, 'Cenobamate', 'Rasagiline', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384508, 'Cenobamate', 'Relugolix', 'Minor', 'Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.', 'DDInter', 1767317475, '-', 'Others', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384509, 'Cenobamate', 'Remifentanil', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384510, 'Cenobamate', 'Remimazolam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384511, 'Cenobamate', 'Repaglinide', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of repaglinide, which is metabolized by the isoenzyme in the intestine and liver.', 'DDInter', 1767317475, 'Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, patients treated concomitantly with rifampin may require a higher dosage of repaglinide. Blood glucose should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy in patients stabilized on their existing antidiabetic regimen, and the repaglinide dosage adjusted as necessary. Patients should be advised to contact their physician if they experience loss of glycemic control.', 'Metabolism', 'Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, patients treated concomitantly with rifampin may require a higher dosage of repaglinide.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384512, 'Cenobamate', 'Ribociclib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ribociclib, which is a substrate of the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished therapeutic effects of ribociclib should be considered when prescribed with inducers of CYP450 3A4, particularly moderate inducers including efavirenz and nevirapine. Pharmacologic effects of ribociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy. Alternative treatment may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished therapeutic effects of ribociclib should be considered when prescribed with inducers of CYP450 3A4, particularly moderate inducers including efavirenz and nevirapine.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384513, 'Cenobamate', 'Rifabutin', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384514, 'Cenobamate', 'Rilpivirine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, caution and clinical monitoring may be advisable if CYP450 3A4 inducers are coadministered with rilpivirine.', 'Metabolism', 'To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, caution and clinical monitoring may be advisable if CYP450 3A4 inducers are coadministered with rilpivirine.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384515, 'Cenobamate', 'Rimegepant', 'Major', 'Coadministration with strong or moderate inducers of CYP450 3A4 may significantly reduce the plasma concentrations and therapeutic effects of rimegepant, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Coadministration of rimegepant with strong or moderate inducers of CYP450 3A4 should be avoided.', 'Metabolism', 'Coadministration of rimegepant with strong or moderate inducers of CYP450 3A4 should be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384516, 'Cenobamate', 'Riociguat', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of riociguat, which is partially metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished therapeutic effects of riociguat should be considered when prescribed in combination with CYP450 3A4 inducers. Patients should be closely monitored, and the dosage of riociguat adjusted as necessary. Data are not available to guide dosing of riociguat when coadministered with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort. Alternative agents with no or minimal CYP450 3A4-inducing activity should be considered whenever possible.', 'Metabolism', 'The potential for diminished therapeutic effects of riociguat should be considered when prescribed in combination with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384517, 'Cenobamate', 'Ripretinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and anti-tumor activities of ripretinib and its active metabolite (DP-5439). The proposed mechanism is induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.', 'DDInter', 1767317475, 'Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the ripretinib dosage adjusted as necessary. Patients should be monitored for loss of anti-tumor activity.', 'Metabolism', 'Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384518, 'Cenobamate', 'Risperidone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384519, 'Cenobamate', 'Ritonavir', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384520, 'Cenobamate', 'Rivaroxaban', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of rivaroxaban, which is a substrate of the isoenzyme as well as the efflux transporter.', 'DDInter', 1767317475, 'Caution is advised if rivaroxaban is used in combination with inducers of CYP450 3A4 and/or P-glycoprotein. Pharmacologic effects of rivaroxaban should be monitored more closely whenever the inducer is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if rivaroxaban is used in combination with inducers of CYP450 3A4 and/or P-glycoprotein.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384521, 'Cenobamate', 'Roflumilast', 'Moderate', 'Coadministration with cenobamate may increase the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19.', 'DDInter', 1767317475, 'Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when cenobamate is used concurrently with drugs that are substrates of CYP450 2C19, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384522, 'Cenobamate', 'Rolapitant', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of rolapitant, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of rolapitant should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of rolapitant should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384523, 'Cenobamate', 'Romidepsin', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384524, 'Cenobamate', 'Ropinirole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384525, 'Cenobamate', 'Rotigotine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384526, 'Cenobamate', 'Rufinamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384527, 'Cenobamate', 'Ruxolitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'No dosage adjustment is recommended when ruxolitinib is coadministered with a CYP450 3A4 inducer. However, patients should be closely monitored and the dose titrated based on safety and efficacy.', 'Metabolism', 'No dosage adjustment is recommended when ruxolitinib is coadministered with a CYP450 3A4 inducer.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384528, 'Cenobamate', 'Saquinavir', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384529, 'Cenobamate', 'Saxagliptin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of saxagliptin, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Dosage adjustment of saxagliptin is not necessary during coadministration with rifampin or other CYP450 3A4 inducers. However, glycemic control should be closely monitored, and the physician notified if an interaction is suspected.', 'Metabolism', 'Dosage adjustment of saxagliptin is not necessary during coadministration with rifampin or other CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384530, 'Cenobamate', 'Secobarbital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384531, 'Cenobamate', 'Selegiline', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 2B6 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 2B6 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384532, 'Cenobamate', 'Selpercatinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of selpercatinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of selpercatinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384533, 'Cenobamate', 'Selumetinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3.', 'DDInter', 1767317475, 'Concomitant use of selumetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of selumetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384534, 'Cenobamate', 'Sertraline', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384535, 'Cenobamate', 'Sibutramine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384536, 'Cenobamate', 'Sildenafil', 'Moderate', 'Theoretically, coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme. The possibility of a diminished therapeutic response to sildenafil should be considered.', 'DDInter', 1767317475, 'Pharmacologic response to sildenafil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the sildenafil dosage adjusted if necessary.', 'Metabolism', 'Pharmacologic response to sildenafil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the sildenafil dosage adjusted if necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384537, 'Cenobamate', 'Silodosin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of silodosin, which is a substrate of both the isoenzyme and efflux transporter.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of silodosin should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of silodosin should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384538, 'Cenobamate', 'Siponimod', 'Major', 'Coadministration with drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 may decrease the plasma concentrations of siponimod, which is primarily metabolized by these isoenzymes. This interaction includes concomitant use of siponimod with a moderate CYP450 2C9/strong CYP450 3A4 dual inducer or a moderate CYP450 2C9 inducer in combination with a separate strong CYP450 3A4 inducer.', 'DDInter', 1767317475, 'Concomitant use of siponimod and drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 (e.g., carbamazepine, enzalutamide, rifampin) is not recommended for all patients. Concomitant use of siponimod and moderate or strong CYP450 3A4 inducers (e.g., apalutamide, bosentan, dabrafenib, dexamethasone, efavirenz, eslicarbazepine, etravirine, fosphenytoin, lorlatinib, lumacaftor, mitotane, modafinil, nafcillin, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifapentine, St. John''s wort) is not recommended for patients with CYP450 2C9*1/*3 and *2/*3 genotypes.', 'Metabolism', 'Concomitant use of siponimod and drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 (e.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384539, 'Cenobamate', 'Sirolimus', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus and tacrolimus, both of which are primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers. Sirolimus and tacrolimus blood levels should be checked frequently and the dosage adjusted accordingly whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384540, 'Cenobamate', 'Sodium oxybate', 'Major', 'The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered.', 'DDInter', 1767317475, 'Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible. Otherwise, close monitoring and/or dosage reductions should be considered. If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.', 'Synergism', 'Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384541, 'Cenobamate', 'Solifenacin', 'Moderate', 'Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of solifenacin, which has been shown to be a substrate of the isoenzyme in vitro.', 'DDInter', 1767317475, 'Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.', 'Metabolism', 'Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384542, 'Cenobamate', 'Sonidegib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of sonidegib with potent and moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of sonidegib with potent and moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384543, 'Cenobamate', 'Sorafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sorafenib, which is partially metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of sorafenib should be considered during coadministration with CYP450 3A4 inducers.', 'Metabolism', 'The potential for diminished pharmacologic effects of sorafenib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384544, 'Cenobamate', 'St. John''s Wort', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384545, 'Cenobamate', 'Stiripentol', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384546, 'Cenobamate', 'Sufentanil', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384547, 'Cenobamate', 'Sunitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sunitinib and its pharmacologically active metabolite, both of which are substrates of the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or dose increase for sunitinib may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384548, 'Cenobamate', 'Suvorexant', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of suvorexant should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and the suvorexant dosage adjusted as necessary.', 'Metabolism', 'The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384549, 'Cenobamate', 'Tacrolimus', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus and tacrolimus, both of which are primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers. Sirolimus and tacrolimus blood levels should be checked frequently and the dosage adjusted accordingly whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384550, 'Cenobamate', 'Tadalafil', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers. However, the possibility of diminished pharmacologic effects of tadalafil should be considered. For the treatment of pulmonary arterial hypertension, use of tadalafil should be avoided in patients chronically taking potent inducers of CYP450 3A4.', 'Metabolism', 'For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384551, 'Cenobamate', 'Tamoxifen', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', 'DDInter', 1767317475, 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384552, 'Cenobamate', 'Tamsulosin', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384553, 'Cenobamate', 'Tapentadol', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384554, 'Cenobamate', 'Tasimelteon', 'Moderate', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.', 'DDInter', 1767317475, 'The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384555, 'Cenobamate', 'Tazemetostat', 'Major', 'Coadministration with moderate or potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible.', 'Metabolism', 'Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384556, 'Cenobamate', 'Telaprevir', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, which are metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer. Close clinical monitoring of the virologic response to the HCV NS3/4A protease inhibitor is recommended.', 'Metabolism', 'Caution is recommended if boceprevir or telaprevir is used in combination with a CYP450 3A4 inducer.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384557, 'Cenobamate', 'Telithromycin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of telithromycin, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished therapeutic effects of telithromycin should be considered when prescribed with CYP450 3A4 inducers. Pharmacologic response to telithromycin should be monitored closely during coadministration, and alternative treatment given if an interaction is suspected. Whenever possible, telithromycin should preferably not be used during or within 2 weeks after discontinuation of treatment with a CYP450 3A4 inducer.', 'Metabolism', 'The potential for diminished therapeutic effects of telithromycin should be considered when prescribed with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384558, 'Cenobamate', 'Temazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384559, 'Cenobamate', 'Temsirolimus', 'Moderate', 'Coadministration of temsirolimus with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.', 'DDInter', 1767317475, 'In the setting of mantle cell lymphoma, concomitant use of temsirolimus with inducers of CYP450 3A4 should generally be avoided. When used for the treatment of renal cell carcinoma, some authorities advise a dose increase from the recommended 25 mg IV once weekly to 50 mg IV once weekly depending on patient tolerability. The dosage should be reduced to the normally recommended dose following discontinuation of the potent CYP450 3A4 inducer.', 'Metabolism', 'In the setting of mantle cell lymphoma, concomitant use of temsirolimus with inducers of CYP450 3A4 should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384560, 'Cenobamate', 'Teniposide', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384561, 'Cenobamate', 'Terfenadine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384562, 'Cenobamate', 'Tetrabenazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384563, 'Cenobamate', 'Thalidomide', 'Moderate', 'Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression.', 'DDInter', 1767317475, 'Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics. Patients should be advised to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Dosage reductions may be necessary. Thalidomide should preferably be administered at bedtime to reduce the impact of somnolence. Alcohol use is not recommended.', 'Synergism', 'Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384564, 'Cenobamate', 'Thiethylperazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384565, 'Cenobamate', 'Thiopental', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384566, 'Cenobamate', 'Thioridazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384567, 'Cenobamate', 'Thiothixene', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384568, 'Cenobamate', 'Tiagabine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384569, 'Cenobamate', 'Ticagrelor', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of ticagrelor with CYP450 3A4 inducers should generally be avoided. Otherwise, caution is advised, and patients should be closely monitored for diminished clinical response to ticagrelor therapy. Alternative treatment may be required if an interaction is suspected.', 'Metabolism', 'Concomitant use of ticagrelor with CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384570, 'Cenobamate', 'Tinidazole', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384571, 'Cenobamate', 'Tipranavir', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384572, 'Cenobamate', 'Tizanidine', 'Moderate', 'The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects. In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation. Tizanidine itself is a central alpha-2 adrenergic agonist. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.', 'DDInter', 1767317475, 'Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position. Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.', 'Synergism', 'Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384573, 'Cenobamate', 'Tofacitinib', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of tofacitinib, which is primarily metabolized by the isoenzyme. The interaction may result in loss of or reduced clinical response; however, the extent to which these medications interact with tofacitinib has not been established.', 'DDInter', 1767317475, 'Caution is recommended if tofacitinib is to be used in combination with moderate CYP450 3A4 inducers. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended when possible.', 'Metabolism', 'Caution is recommended if tofacitinib is to be used in combination with moderate CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384574, 'Cenobamate', 'Tolcapone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384575, 'Cenobamate', 'Tolterodine', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384576, 'Cenobamate', 'Tolvaptan', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tolvaptan, which is primarily metabolized by the isoenzyme. When tolvaptan was administered with the potent CYP450 3A4 inducer rifampin, tolvaptan peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 85%.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of tolvaptan should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of tolvaptan should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384577, 'Cenobamate', 'Topiramate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384578, 'Cenobamate', 'Toremifene', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of toremifene. According to the product labeling, toremifene is primarily metabolized by CYP450 3A4 to N-demethyltoremifene, an antiestrogenic metabolite with weak in vivo antitumor potency but whose serum concentrations are 2 to 4 times higher than those of toremifene at steady state. The extent to which other, less potent CYP450 3A4 inducers may affect toremifene is unknown.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of toremifene should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or a dose adjustment of toremifene may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of toremifene should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384579, 'Cenobamate', 'Trabectedin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.', 'Metabolism', 'The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384580, 'Cenobamate', 'Tranylcypromine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384581, 'Cenobamate', 'Trazodone', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384582, 'Cenobamate', 'Tretinoin', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384583, 'Cenobamate', 'Triazolam', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384584, 'Cenobamate', 'Trifluoperazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384585, 'Cenobamate', 'Triflupromazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384586, 'Cenobamate', 'Trihexyphenidyl', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384587, 'Alimemazine', 'Cenobamate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384588, 'Cenobamate', 'Trimethadione', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384589, 'Cenobamate', 'Trimethobenzamide', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384590, 'Cenobamate', 'Trimipramine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384591, 'Cenobamate', 'Tripelennamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384592, 'Cenobamate', 'Triprolidine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 1767317475, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1384593, 'Cenobamate', 'Troglitazone', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, NULL, 'Moderate', 'pharmacodynamic');
